High-dimensional immunoprofiling data visualisation for biologic development and vaccine development projects.

High-dimensional immunoprofiling - with machine learning insights - for complex vaccines and biologics

We're here to help vaccine and biologic teams get clearer, more actionable insights into immune responses. Using advanced peptide and protein microarrays, we capture thousands of antibody binding patterns from tiny serum samples.What sets us apart is our integrated machine learning and AI approaches - these turn complex data into practical predictions, like early immunogenicity signals, response durability, and antigen prioritisation.It's all about de-risking your pipeline and speeding up better decisions, especially for challenging multi-component or bacterial vaccines.

ImmunoSig Ltd. is a company incorporated in England and Wales. Company No. 16642090.
3rd Floor 86-90 Paul Street, London, EC2A 4NE
© 2025 All rights reserved. ImmunoSig Ltd. Privacy Notice

Our biologic & vaccine immunoprofiling platformHow It Works: From Sample to Insight

Peptide microarray services workflow demonstrating steps for accurate immunogenicity assessment.

How It Works: Biologic formulation package

Peptide microarray technology used for high-throughput epitope mapping services.

How It Works: Immunoprofiling package

Peptide microarray technology used for high-throughput epitope mapping services.
Prof. Jeremy Derrick, Co-Founder: Expert in vaccine development and antibody characterisation services.

Prof. Jeremy Derrick
Co-Founder

Jeremy obtained his first degree and PhD from the University of Cambridge. He was appointed a Lecturer at UMIST in Manchester in 1993 and was a Lister Institute Fellow from 1996 to 2001. He joined the University of Manchester in 2003, when the two universities merged. He has worked extensively on protein structure and function, publishing more than 130 peer-reviewed papers. He has served on multiple grant panels, and is continually requested to act as a reviewer for major scientific journals. More recently, he has applied his extensive commercial experience to projects in immunoprofiling, vaccine development, and biologic formulation

Fidel Ramirez Bencomo expert in vaccine development and antibody characterisation services.

Dr Fidel Ramirez Bencomo
Co-founder

Fidel graduated in Biochemistry and Molecular Biology from the University of Havana and earned a PhD in Microbiology from the University of Manchester. With over 10 years’ experience, he specialises in monoclonal antibody production, diagnostic assay development, and protein microarrays. Fidel’s work at the Finlay Vaccine Institute (Cuba) and in the University of Manchester focuses on immunoprofiling, epitope mapping, and vaccine development. He has led projects supported by GSK and the Bill and Melinda Gates Foundation, and has presented at major conferences and published numerous peer-reviewed papers.

Contact Us Today to Accelerate Your Immunoprofiling Research

Ready to explore how AI-enhanced immunoprofiling can support your project? Get in touch - we'd love to chat about your needs.

Thank you

Thank you for your message. We will reply to you within 2-3 business days.

Thank you

Thank you for requesting our launch webinar. The link will be landing in your inbox soon. Looking forward to your feedback.

Privacy notice

ImmunoSig Ltd is committed to protecting your privacy. We collect only the information necessary to provide our services, communicate with clients, and maintain regulatory compliance. Any personal data shared with us is processed securely and never sold or disclosed to third parties, except where required by law or for the delivery of essential services.You can review the full details of our data practices, retention policies, and your rights under UK GDPR in our Privacy Policy document below.

Frequently Asked Questions (FAQs)

What is your immunoprofiling analysis and how does it differ from traditional approaches?
Our immunoprofiling looks at the full pattern of immune responses across hundreds or thousands of antigens at once. Traditional methods usually test just 5-10 hand-picked ones. We use peptide and protein microarray technology, combined with machine learning, to screen a carefully selected set of antigens and reveal which ones could drive protective immunity, especially in complex vaccines and bacterial infections with 2,000+ potential targets.
What services do you offer?
We focus on three main areas:

Complex Vaccine Immunoprofiling – Pinpointing antigen combinations in multi-component and whole-cell vaccines that could generate protective responses

Bacterial Infection Profiling – Mapping immune responses to complex bacterial pathogens with hundreds of antigens

Machine Learning-Enhanced Analysis – Our advanced ML tools spot hidden antigen interactions and predict synergistic combinations

Every project includes full bioinformatics support and clear data packages to help refine your hypotheses.
How long does a project take?
We design and produce custom microarrays for each project, no off-the-shelf panels. Timelines vary depending on complexity (array design, printing, QC, and analysis).

Tell us about your needs, and we'll give you a realistic estimate tailored to your design and goals.
What sample volume and type do you need?
We keep requirements low to save your valuable samples:

Serum/Plasma: 10-20 μL per sample
Purified antibodies: 10-50 μg (depending on affinity)
Cell culture supernatants: 100-200 μL

We accept serum, plasma, CSF, and purified antibodies, either fresh or frozen. We'll send clear preparation guidelines when we start.
What quality standards do you follow?
We maintain strict research-grade quality controls:

• Full documentation and audit trails
• Standardized protocols with built-in controls
• Statistical reports plus raw data in multiple formats
• In-depth bioinformatics insights

Note: Our work supports discovery and hypothesis generation. For regulatory or clinical use, you'll need to validate through your own compliant processes.
How does your approach compare to traditional antigen screening?
Our microarray immunoprofiling has clear advantages:

Scale: Screen 100+ antigens vs. 5–10 traditionally

Unbiased discovery: Finds unexpected protective antigens

Sample efficiency: Just 10-20 μL vs. mL for multiple ELISAs

Combination insights: Machine Learning (ML) reveals synergistic antigens

Cost: Much lower per antigen tested

Targeted assays are still great for validation, but we're unmatched for complex antigen discovery.
Can you help with complex vaccine projects?
Yes, that's our sweet spot. We support:

• Optimizing multi-component vaccines (include/exclude decisions)
• Characterizing whole-cell vaccines
• Selecting bacterial antigens from full proteomes
• Guiding combination vaccine formulations
• Spotting synergistic or redundant antigens
• Diagnostic panel development

Our ML analysis turns guesswork into data-driven choices.
How does machine learning improve your analysis?
Raw data shows reactive antigens, but the real questions are harder: Which ones work together? Which combinations predict protection?

Our ML models:

• Find combinations linked to outcomes
• Detect non-linear interactions
• Predict optimal antigen sets
• Separate protective from non-protective patterns
• Handle cross-reactivity

We make complex data truly actionable.
How are you different from other microarray providers?
We use similar peptide/protein microarray platforms but go further with advanced machine learning.

Standard output: "Here are hundreds of reactive antigens"

Our output: "Here are the key antigen combinations that correlate with protection - ranked, with synergy insights"

What sets us apart:
1. ML-driven combination analysis
2. Focus on complex, multi-antigen vaccines
3. Deep vaccine development experience on our team
How do I get started?
It's straightforward:

1. Book a quick consultation call (15-30 min) to discuss your goals

2. We'll send a detailed proposal (design, timeline, deliverables, pricing) within a few days

3. Approve and we start array production

4. Get comprehensive results with figures ready for presentations or publications

Contact us today - we're happy to chat.
What vaccines and pathogens do you work with?
We're especially helpful for complex cases:

• Whole-cell bacterial vaccines (meningitis, gonorrhoeae, pertussis, typhoid, cholera, etc.)
• Multi-component combinations
• TB candidates
• Bacterial immunology (Streptococcus, Staphylococcus, E. coli, etc.)
• Parasites, fungi, veterinary vaccines
• Diagnostic antigen discovery

If you're wondering which antigens actually matter out of hundreds - we're here to help.
Can you handle confidential sequences?
Absolutely. We regularly work with proprietary antibodies, unpublished antigens, and sensitive biologics. All projects include robust confidentiality agreements, and we can adapt to special security needs.

Launch webinar

Missed the ImmunoSig launch?
You can now watch the full webinar on demand.In this session we walked through how ImmunoSig’s high-resolution peptide and protein microarray platform delivers detailed immunoprofiles for vaccine and biologics development.
You’ll see how our approach can be applied to identify key immune signatures, compare candidates, and generate data that supports faster, clearer decision-making.Watch the recording anytime and see how ImmunoSig can strengthen your next project.